Drug treatment in type 2 diabetes (part 2)

Insulin secretagogues and insulin sensitizers can be combined with one another as well as with other treatments (described below). Alpha-glucosidase inhibitors delay intestinal absorption of carbohydrates and reduce postprandial glycemia. Orlistat and sibutramine improve insulin sensitivity by helpi...

Full description

Saved in:
Bibliographic Details
Published inLa Presse médicale (1983) Vol. 36; no. 3 Pt 2; pp. 467 - 474
Main Authors Tielmans, Amélie, Virally, Marie, Coupaye, Muriel, Laloi-Michelin, Marie, Méas, Taly, Guillausseau, Pierre-Jean
Format Journal Article
LanguageFrench
Published France 01.03.2007
Subjects
Anti-Obesity Agents - therapeutic use
Diabetes Mellitus, Type 2 - drug therapy
Glycoside Hydrolase Inhibitors
Humans
Insulin - therapeutic use
Online AccessGet full text

Cover

More Information
Summary:Insulin secretagogues and insulin sensitizers can be combined with one another as well as with other treatments (described below). Alpha-glucosidase inhibitors delay intestinal absorption of carbohydrates and reduce postprandial glycemia. Orlistat and sibutramine improve insulin sensitivity by helping patients lose weight. Orlistat inhibits hydrolysis of dietary triglycerides. Sibutramine, a noradrenaline and serotonin reuptake inhibitor, reinforces feelings of satiety and increases energy expenditure. After approximately 10 years, insulin therapy is usually required together with oral antidiabetic agents (except glitazones) or alone if HbA(1c) (glycosylated hemoglobin) is>6.5%. New guidelines for management of type 2 diabetes were published in 2006.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-3
content type line 23
ISSN:0755-4982
DOI:10.1016/j.lpm.2006.11.015